Marta
Llanos Muñoz
Profesora Asociada Asistencial
Hospital del Mar
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital del Mar (5)
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
2010
-
Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma
Blood, Vol. 116, Núm. 8